Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma.
Xiaoqing SunJianghua CaoPeng SunHang YangHuan LiWenjuan MaXianqiu WuXiaohua HeJing LiZhi-Ming LiJiajia HuangPublished in: Biomarkers in medicine (2023)
Aims: To explore the clinical association between soluble Siglec-5/CD163 and clinical feature and prognosis in peripheral blood samples of patients with diffuse large B-cell lymphoma. Method: Significantly elevated cytokines in peripheral blood were characterized by cytokines array and validated by ELISA. Results: Compared with CD163, Siglec-5 exhibited superiority in discriminating patients into low- and high-risk subgroups based on overall survival and progression-free survival. In addition, Siglec-5 was an indicator of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment efficacy. Conclusion: Siglec-5 may be applied as a reliable independent immune indicator for overall survival and progression-free survival. It may also predict R-CHOP efficacy in diffuse large B-cell lymphoma.
Keyphrases
- diffuse large b cell lymphoma
- free survival
- peripheral blood
- epstein barr virus
- end stage renal disease
- machine learning
- low dose
- ejection fraction
- chronic kidney disease
- high throughput
- peritoneal dialysis
- high resolution
- drug delivery
- high dose
- combination therapy
- patient reported
- smoking cessation
- protein protein